Simon J. Clark

New discovery: FHR1, a complement system protein, plays a surprising role in helping macrophages clear dead cells (efferocytosis). #FHR1 #Immunology #Macrophages #Proteomics #Biotech #ComplementSystem #SingleCell buff.ly/KkCkG9e

New study shows why not all #DME responds to anti-VEGF. CMD (cystoid macular degeneration) resists treatment—linked to apoptosis, complement activation & lipid metabolism. DRT/CME fare better, tied to Wnt & ECM signalling. #Ophthalmology #Retina #Diabetes buff.ly/Jhot42I

🧬 New study links genetic risk scores to retinal damage in AMD. Using OCT imaging, researchers found: 🔹 Complement genes → early signs (drusen) 🔹 ARMS2/HTRA1 → advanced atrophy 🔹 Global scores predict disease severity #AMD #Genetics #Ophthalmology buff.ly/2tz6L0o

This is an...interesting approach - inravenous (IV) delivery of an anti-PRL3 humanised antibody to treat CNV in wet AMD 😳 . Some good pre-clinical data in CNV models, but I wonder about IV delivery for treating eye disease. #CNV #cancer #AMD buff.ly/6van15v

recent study uses AI to assess risk genotypes from AMD fundus images. However, their genetic dataset lacks recent risk SNPs, such as CFH intronic SNP rs10922109. Promising start but needs to include the latest genetic risk factors. #AMD #AI #CFH #ARMS2 buff.ly/bpKp6am

Review highlights new immune checkpoint found in the eye. Loss of sialylation triggers complement-mediated damage in AMD. Preclinical rescue via polysialic acid delivery = preserved retinal cells + reduced inflammation. #Biotech #Immunotherapy #AMD buff.ly/17SpdAK

Recent study shows FH serum as a marker for Cutaneous Squamous Cell Carcinoma progression. However, their FH baseline of 122–895 pg/ml seems off; typical levels are 250-750 ug/ml. Why the discrepancy? #complement #FH #cancer #prognosis buff.ly/fLik0Vh

Intravitreal injections save vision—but sterile intraocular inflammation is a growing concern. Linked to brolucizumab & complement inhibitors, it can mimic infection & cause serious damage. Timely diagnosis + steroids = key. #Ophthalmology #Retina buff.ly/JCZoWf6

Alcon has acquired the Valeda photobiomodulation devise, using low-level light to help stimulate mitochondrial activity in the cells of the retina, marking a pivotal expansion into non-invasive therapies for early and intermediate dry AMD. #DryAMD buff.ly/3TaZW5f

Rallybio is exiting its Recursion/Exscientia partnership on REV102, to refocus on its C5 inhibitor, RLYB116. Will the once-weekly subcutaneously delivered C5 inhibitor sufficiently down regulate systemic complement? #C5inhibitor #Biotech #RareDisease buff.ly/k73uNfd

First patient dosed with PulseSight's non viral vectorised therapy to overexpress transferrin to treat GA in AMD. How well this elctro-transfection technique acts as a delivery method for non-viral gene therapies? #AMD #GA #genetherapy buff.ly/02NTnts

Interesting study describing the potential use of a C3d-antibody to hone therapeutic delivery to the kidney's of aHUS patients. A number of advantages over systemic targeting of complement for an organ-specific disease. #aHUS #CR1 #complement buff.ly/nISOz9S

4DMT puts everything on the line for its bicistronic approach delivering aflibercept and siRNA against VEGF-C. Does this include pausing its 4D-175 asset delivering shortened FH in GA? #wetAMD #CNV #aflibercept #AAV buff.ly/bEiInJe

Cool study investigating the role of FHR-1 in AMD - with comparisons to murine FHR1 homologue too. Appears to have subtly different localisation profile compared to FHR-2, -4, and -5 as seen in other studies, but its there! #AMD #FHR #ophthalmology buff.ly/UkgTd7s

EU okays extended treatment interval for Bayer, Regeneron's higher-dose Eylea buff.ly/4Yn1bT6 This will move the goalposts for assets whose USP is less frequent dosing. How much better are they going to have to be now? Once a year? #wetAMD #antiVEGF #eylea

Despite the layoffs and lab closures at BlueRock, their ocular asset OpCT-001, an investigational iPSC-derived cell therapy, should not be affected. OpCT-001 entered phase I/II trials earlier this year. #celltherapy #ophthalmology #clinicaltrials buff.ly/ZbNGTwr

Stuart Therapeutics’ dry eye drug ST-100 failed its Phase 3 trial. Despite promising Phase 2 data, the novel collagen-repair eyedrop didn’t meet endpoints. They plan another study—but it’s a tough road in #DryEyeDisease R&D. #Biotech #Ophthalmology buff.ly/2zLBazo